Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Treatment Resistant Major Depression Clear all
Active, not recruiting Phase 2 Interventional

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

NCT05774665
View directory record Official record
Conditions
Treatment Resistant Depression, Inflammation, Overweight
Interventions
Omega 3, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 7:13 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

NCT06480201
View directory record Official record
Conditions
Healthy, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
21 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 2 Interventional Results available

Optimization of IV Ketamine for Treatment Resistant Depression

NCT00768430
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 21, 2026, 7:13 AM EDT
Terminated Phase 2 Interventional Results available

Salicylic Augmentation in Depression

NCT03152409
View directory record Official record
Conditions
Depression, Depressive Disorder, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Aspirin 325mg, Placebo Oral Tablet
Drug
Lead sponsor
Jessica Harder
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Not applicable Interventional Results available

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

NCT02522377
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 2 Interventional Results available

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

NCT00633399
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 21, 2026, 7:13 AM EDT
Active, not recruiting No phase listed Observational

Open Label Optimization Study

NCT05819021
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAINT® Neuromodulation System (NMS)
Device
Lead sponsor
Magnus Medical
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Costa Mesa, California • Los Angeles, California • Sunnyvale, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 21, 2026, 7:13 AM EDT
Terminated Phase 2 Interventional

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01361555
View directory record Official record
Conditions
Depression
Interventions
Placebo matching with BMS-820836, BMS-820836
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
94
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 4 Interventional

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT05615948
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
Interventions
VTS-K
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

NCT05220410
View directory record Official record
Conditions
Treatment Resistant Depression, Suicidal Ideation
Interventions
Psilocybin
Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

NCT00953745
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 21, 2026, 7:13 AM EDT
Not yet recruiting Not applicable Interventional

Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression

NCT07528157
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Personalized iTBS, Non-Personalized iTBS, Sham iTBS
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 2 Interventional Results available

Targeting IL-17A for Treatment-Resistant Depression

NCT04979910
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ixekizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 1 Interventional Results available

KET-RO Plus RO DBT for Treatment Resistant Depression

NCT06138691
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine Infusion plus RO DBT
Combination Product
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 1 Interventional

Home-administered tDCS for Treatment of Depression

NCT04781127
View directory record Official record
Conditions
Unipolar Depression, Treatment Resistant Depression
Interventions
Soterix Medical mini-CT tDCS stimulator
Device
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 21, 2026, 7:13 AM EDT
Terminated Phase 4 Interventional Results available

N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression

NCT01260649
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ketamine, IV Saline, ECT, Muscle Relaxant, Anesthetic Agents
Drug · Other · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 21, 2026, 7:13 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

NCT06524830
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
VLS-01-203 BU, VLS-01-BU Placebo
Drug
Lead sponsor
atai Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Not applicable Interventional

Ketamine Anesthesia for Improvement of Depression in ECT

NCT02752724
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Methohexital
Drug
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 2 Interventional Results available

Ketamine Plus Lithium in Treatment-Resistant Depression

NCT01880593
View directory record Official record
Conditions
Depression
Interventions
Lithium, Ketamine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Phase 2 Interventional Results available

Nuedexta in Treatment-Resistant Major Depression

NCT01882829
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant
Interventions
dextromethorphan/quinidine
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Early Phase 1 Interventional

Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

NCT01601210
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine monohydrate or placebo
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 21, 2026, 7:13 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

NCT04634669
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 21, 2026, 7:13 AM EDT
Completed Not applicable Interventional

Lamotrigine Augmentation in Resistant Depression

NCT00901407
View directory record Official record
Conditions
Unipolar Depression
Interventions
lamotrigine, placebo, paroxetine
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Oct 21, 2026, 7:13 AM EDT